SWOG S1505
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
- NCT02562716 ↗
- Completed
- SWOG Cancer Research Network
- Deep
We haven't built an HCP commentary report on SWOG S1505 (mFOLFIRINOX; gemcitabine plus nab-paclitaxel in resectable pancreatic adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SWOG S1505 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 28 | |
| Podcasts | 5 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Pancreatic Adenocarcinoma; Resectable Pancreatic Carcinoma
- Interventions
- Fluorouracil; Gemcitabine Hydrochloride; Irinotecan Hydrochloride; Oxaliplatin; Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Pancreatectomy
- Arms
- Arm I (mFOLFIRINOX, surgery) · Experimental
- Arm II (gemcitabine, nab-paclitaxel, and surgery) · Experimental
- Enrollment
- 147
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- Jan 6, 2016
- Primary completion
- May 31, 2020
- Results posted
- Yes
- Registry record
- NCT02562716 · updated Oct 19, 2022
Publications
linked from the registry- Sohal DPS, Boutin RD, Lenchik L, Kim J, Beg MS, Wang-Gillam A, Wade JL 3rd, Guthrie KA, Chiorean EG, Ahmad SA, Lowy AM, Philip PA, Chang VT. Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505. J Gastrointest Surg. 2024 Mar;28(3):232-235. doi: 10.1016/j.gassur.2023.12.022. Epub 2024 Jan 19. PubMed 38445914
- Sohal DPS, Duong M, Ahmad SA, Gandhi NS, Beg MS, Wang-Gillam A, Wade JL 3rd, Chiorean EG, Guthrie KA, Lowy AM, Philip PA, Hochster HS. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Mar 1;7(3):421-427. doi: 10.1001/jamaoncol.2020.7328. PubMed 33475684
- Ahmad SA, Duong M, Sohal DPS, Gandhi NS, Beg MS, Wang-Gillam A, Wade JL 3rd, Chiorean EG, Guthrie KA, Lowy AM, Philip PA, Hochster HS. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma. Ann Surg. 2020 Sep 1;272(3):481-486. doi: 10.1097/SLA.0000000000004155. PubMed 32740235